Eli Lilly and Co. pulled ahead in a three-way race with Amgen Inc. and Teva Pharmaceutical Industries Ltd. in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that the company’s therapy can completely prevent headaches in a small percentage of patients.
Expectations were high during 2018 for three new migraine drugs hitting the market from Amgen Inc., Eli Lilly and Co. and Teva Pharmaceutical Industries Ltd. Priced around $7,000 each, the drugmakers called them “breakthrough” treatments designed to prevent migraines when taken year-round, and estimated that millions of patients could benefit. But a small group of medical experts who quietly advise U.S. health insurers on new drugs was not impressed, according to a private meeting held at UnitedHealth Group’s OptumRx offices in Chicago that was attended by Reuters.
The pharmaceutical industry’s greatest value lies in the quality of life that its drugs provide – plus the innovative programs that help support adherence and education.
A mutual health aid plan launched by Ant Financial Services Group – the dominant fintech player in China – has amassed more than 50 million users and is aiming for 300 million within two years, the company said.
Health insurer Cigna Corp. launched a program aimed at ensuring some diabetes patients pay no more than $25 for a 30-day supply of insulin in the wake of heightened public scrutiny over soaring prices of the life-saving drug.
Centene Corp. will buy smaller rival WellCare Health Plans Inc. for $15.27 billion in stock and cash, in a move to bulk up the U.S. health insurer’s government-backed Medicare and Medicaid businesses while reducing exposure to Obamacare healthcare exchanges.
Participating in the Blue Cross Blue Shield Alliance for Health Research, the study comes from Yale’s School of Public Health and School of Medicine NEW HAVEN, Conn., March 22, 2019 /PRNewswire/ –State breast density notification laws that mandate reporting of mammogram results can prompt further screening and modestly boost cancer detection rates, say […]
Sanofi SA and Regeneron Pharmaceuticals Inc. will slash the U.S. list price of the companies’ potent but expensive cholesterol fighter Praluent by 60 percent.
As lawmakers in Congress are exploring potential price-lowering options for prescription drugs, Department of Health and Human Services Secretary Alex Azar is floating a proposed rule to lower the prices and out-of-pocket expenses by encouraging manufacturers to pass discounts to patients instead of insurers.
The U.S. Senate Finance Committee and the House Oversight Committee started hearings focused on high drug prices.